✦ LIBER ✦

A toxinlike material separable from type 5 adenovirus particles

✍ Scribed by Everett, Spaulding F.; Ginsberg, Harold S.

Book ID: 122439195
Publisher: Elsevier Science
Year: 1958
Tongue: English
Weight: 122 KB
Volume: 6
Category: Article
ISSN: 0042-6822
DOI: 10.1016/0042-6822(58)90123-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adenovirus type 5 DNA–protein complexes

Adenovirus type 5 DNA–protein complexes from formaldehyde cross-linked cells early after infection

✍ David J Spector; Jeffrey S Johnson; Nicholas L Baird; Daniel A Engel 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 359 KB

Synthesis of large crystals of ZSM-5 zeo

Synthesis of large crystals of ZSM-5 zeolite from a smectite-type clay material

✍ K. Abdmeziem; B. Siffert 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 578 KB

Thiophilic paramagnetic particles as a b

Thiophilic paramagnetic particles as a batch separation medium for the purification of antibodies from various source materials

✍ Clive C. Dawes; Philip J. Jewess; Deborah A. Murray 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 392 KB

Adenovirus type 5 early region 1B 55-kDa

Adenovirus type 5 early region 1B 55-kDa oncoprotein can promote cell transformation by a mechanism independent from blocking p53-activated transcription

✍ Härtl, B; Zeller, T; Blanchette, P; Kremmer, E; Dobner, T 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 504 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part